A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas

PURPOSE: Oral administration of the alkylating agent cyclophosphamide at low doses, metronomic dosing, is well tolerated, with efficacy in multiple tumor types. Poly(ADP-ribose) polymerase (PARP) inhibition potentiates effects of cyclophosphamide in preclinical models. We conducted a phase I trial o...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Kummar, Shivaani, Ji, Jiuping, Morgan, Robert, Lenz, Heinz-Josef, Puhalla, Shannon L., Belani, Chandra P., Gandara, David R., Allen, Deborah, Kiesel, Brian, Beumer, Jan H., Newman, Edward M., Rubinstein, Larry, Chen, Alice, Zhang, Yiping, Wang, Lihua, Kinders, Robert J., Parchment, Ralph E., Tomaszewski, Joseph E., Doroshow, James H.
Formato: Artigo
Idioma:Inglês
Publicado: 2012
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3306481/
https://ncbi.nlm.nih.gov/pubmed/22307137
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-2821
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares